Useful links

Donation of plasma

  • Who can be registered as blood donors?


    In general, all healthy women who have given birth to an FNAIT child can give blood.  Please read more about the requirements in the Donate plasma section.

  • How do I know if I am immunize against HPA-1a?


    If you have given birth to a child with bleeding symptoms or low platelet count but otherwise healthy, it is likely you have antibodies against HPA-1a. The FNAIT experts at Prophylix Pharmawill be happy to answer your questions and provide further guidance. You can find our contact information on the Contact us page.

  • How is plasma collection carried out?


    Plasma is collected by a special procedure called plasmapheresis.Blood is collected the same way as in a normal blood donation, but during plasmapheresis a special piece of equipment – the apharesis machine – separate plasma from the blood by centrifugation while returning the blood cells (red cells, white cells and blood platelets) to the donor. In other words, you will keep all of your valuable blood cells and only the plasma will be collected. It is usual to collect around 600 ml plasma in one procedure which takes from 30 to 60 min.

  • How does plasma collection affect my health?


    Plasmapheresis is a safe and well proven method which is used for collection of plasma from thousands of donors every day without adverse effects on their health. As the body will quickly regenerate the plasma that has been removed, it is usual to collect plasma one to two times a month.

  • Can all blood centres collect plasma for the PROFNAIT project?


    Only blood banks that are equipped with plasmapheresis machines can collect plasma. Moreover, to ensure the highest level of safety, blood bank shall be approved by the PROFNAIT project participant Biotest AG in order to collect plasma for the project.Currently we have plasma centers in US, Germany, Sweden and Norway.Please visit our project website; to locate your closest plasma centers.

  • Who have approved plasma collection for this particular purpose?


    Plasma collection for the PROFNAIT project will not be initiated before approval has been obtained from the appropriate committees for medical research ethics in every country where plasma collection takes place. All plasma collection will comply with all institutional, regional and national regulations.


Prevention of FNAIT 

  • Which women should receive the prophylaxis against FNAIT?


    The prophylaxis should be administered to pregnant women who have platelets which are HPA-1a negative and who have given birth to a child with HPA-1a positive platelets. These women must initially be identified via a blood test which is performed during their pregnancy. This test is very similar to the Rhesus-typing that is today performed on all pregnant women. Please note that the drug for prevention of FNAIT is still in development and cannot yet be offered to pregnant, HPA-1a negative women.

  • Which women do not need prophylaxis against FNAIT?


    Women who have blood platelets which are HPA 1a positive should not have prophylaxis as they cannot produce anti-HPA-1a that can adversely affect the foetus.


    Prophylaxis should also not be administered to women who are HPA-1a negative and have already produced anti-HPA 1a by themselves. The prophylaxis can only be used to prevent immunization – when anti-HPA-1a is already produced, it is too late with prophylaxis.


    Women who are HPA-1a negative and have give birth to an HPA-1a negative child does not need prophylaxis because there is no risk of immunization since the newborn is HPA 1a negative.

  • Is FNAIT prophylaxis safe?


    For 40 years, anti-D has routinely been administered to RhD-negative women («Rhesus negative» women) after delivery of an RhD positive child («Rhesus positive» child) to prevent the mother from developing anti-D antibodies. Such antibodies can severely affect the foetus in a subsequent pregnancy and cause a serious condition known as haemolytic disease of the foetus and newborn(HDN). Since the therapeutic principle for prevention of FNAIT is similar to prevention of RhD immunization, it is believed that administration of anti-HPA-1a as prophylaxis for FNAIT is both effective and completely safe.